Aug 15, 2024 / 12:00PM GMT
Operator
Greetings and welcome to the Inhibikase Therapeutics second-quarter 2024 financial results conference call. (Operator Instructions) As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Alex Lobo, Precision AQ, Investor Relations. Thank you, sir. You may begin.
Alex Lobo - Precision AQ - Investor Relations
Good morning, and welcome to Inhibikase Therapeutics' second-quarter 2024 financial results conference call and audio webcast. With me today is Dr. Milton Werner, Chief Executive Officer; and Garth Lees-Rolfe, Chief Financial Officer. On August 14, Inhibikase issued a press release announcing financial results for the second quarter ended June 30, 2024.
We encourage everyone to read yesterday's press release as well as in Inhibikase quarterly report on Form 10-Q, which has been filed with the SEC. The company's press release and Form 10-Q are also available on Inhibikase's website and Inhibikase.com. In addition, this conference call is being webcast with the Investor Relations section of the company
Q2 2024 Inhibikase Therapeutics Inc Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
